BackgroundHepatitis C virus (HCV) infection is a global epidemic with an estimated 71 million people infected worldwide. People who inject drugs (PWID) are overrepresented in prison populations globally and have higher levels of HCV infection than the general population. Despite increased access to primary health care while in prison, many HCV infected prisoners do not engage with screening or treatment. With recent advances in treatment regimes, HCV in now a curable and preventable disease and prisons provide an ideal opportunity to engage this hard to reach population.AimTo identify barriers and enablers to HCV screening and treatment in prisons.MethodsA qualitative study of four prisoner focus groups (n = 46) conducted at two prison settings in Dublin, Ireland.ResultsThe following barriers to HCV screening and treatment were identified: lack of knowledge, concerns regarding confidentiality and stigma experienced and inconsistent and delayed access to prison health services. Enablers identified included; access to health care, opt-out screening at committal, peer support, and stability of prison life which removed many of the competing priorities associated with life on the outside. Unique blocks and enablers to HCV treatment reported were fear of treatment and having a liver biopsy, the requirement to go to hospital and in-reach hepatology services and fibroscanning.ConclusionThe many barriers and enablers to HCV screening and treatment reported by Irish prisoners will inform both national and international public health HCV elimination strategies. Incarceration provides a unique opportunity to upscale HCV treatment and linkage to the community would support effectiveness.

Most patients inappropriately continued to receive stress ulcer prophylaxis during post-SICU hospitalization. Presence of risk factors for stress ulcer-related gastrointestinal bleeding at SICU admission appears to influence continuation of AST after discharge from the hospital. A low percentage (3.2%) of patients was discharged home receiving inappropriate AST, yet overall, few study patients demonstrated a compelling risk factor for continuation of AST.

BackgroundHepatitis C virus (HCV) is one of the main causes of chronic liver disease worldwide. Prevalence of HCV in homeless populations ranges from 3.9 to 36.2%. The HepCheck study sought to investigate and establish the characterisation of HCV burden among individuals who attended an intensified screening programme for HCV in homeless services in Dublin, Ireland.MethodsThe HepCheck study was conducted as part of a larger European wide initiative called HepCare Europe. The study consisted of three phases; 1) all subjects completed a short survey and were offered a rapid oral HCV test; 2) a convenience sample of HCV positive participants from phase 1 were selected to complete a survey on health and social risk factors and 3) subjects were tracked along the referral pathway to identify whether they were referred to a specialist clinic, attended the specialist clinic, were assessed for cirrhosis by transient elastography (Fibroscan) and were treated for HCV.ResultsFive hundred ninety-seven individuals were offered HCV screening, 73% were male and 63% reported having had a previous HCV screening. We screened 538 (90%) of those offered screening, with 37% testing positive. Among those who tested positive, 112 (56%) were ‘new positives’ and 44% were ‘known positives’. Undiagnosed HCV was prevalent in 19% of the study sample. Active past 30-day drug use was common, along with attendance for drug treatment. Unstable accommodation was the most common barrier to attending specialist appointments and accessing treatment. Depression and anxiety, dental problems and respiratory conditions were common reported health problems. Forty-six subjects were referred to specialised services and two subjects completed HCV treatment.ConclusionsThis study demonstrates that the current hospital-based model of care is inadequate in addressing the specific needs of a homeless population and emphasises the need for a community-based treatment approach. Findings are intended to inform HepCare Europe in their development of a community-based model of care in order to engage with homeless individuals with multiple co-morbidities including substance abuse, who are affected by or infected with HCV.

24Urinary tract stones are an important clinical problem in human and veterinary 25 medicine. Hyperoxaluria is the single strongest promoter of kidney stone formation. The 26 aims of the present study were to, (a) evaluate oxalate degradation by a range of 27Bifidobacteria species and Lactobacillus species isolated from the canine and feline 28 gastrointestinal tract in vitro and, (b) to determine the impact of oxalate degradation by 29 selected strains in vivo. The bacteria were grown in oxalate-containing media and their 30 ability to degrade oxalate in vitro was determined using reverse-phased HPLC. 31Bifidobacteria species and Lactobacillus species that degraded oxalate in vitro and 32 survived gastric transit were selected for further examination. The selected probiotics 33 were fed to rats for 4 weeks. Urine was collected at week's 0, 2 and 4 and oxalate levels 34 determined by HPLC. In vitro degradation was detected for 11/18 of the Lactobacillus 35 species. In contrast, the capacity to degrade oxalate was not detected for any of the 13 36

The prevalence of asymptomatic C. difficile carriage in this institution was 10%, 7% of which were toxin positive. This study underscores the importance of increased vigilance for C. difficile using microbial and molecular methodology and identifies patients at increased risk following antibiotic administration.

Few studies have assessed the effects of thiazolidinediones on bone in humans. Studies available suggest that treatment with thiazolidinediones, primarily rosiglitazone, contributes to bone loss. The effect appears to be most prominent in postmenopausal women. More studies are needed to better understand the effects of thiazolidinediones on bone and fracture rates.

The study highlights the usefulness of community fibroscanning. Identifying barriers to treatment in this cohort affords an opportunity to increase the treatment uptake. The availability of afternoon clinics and enhanced prison linkage are warranted.

Details of the size, structure and occurrence of Carnponotus intrepidus nests and the size, composition and source of the mound cover on Iridomyrmex purpureus nests are reported from several areas of eastern New South Wales. Both species are common, and construct large mounds of mixed topsoil and subsoil with surface covers, which appear to protect the mound from rainsplash erosion. Camponotus thatches the mound with charcoal, leaves and twigs; Iridomyrmex covers the mound in granules of inorganic or organic material that are sufficiently large to absorb most raindrop impact energy. This material is collected from the surface and carried 10-15 m to the nest. Rainsplash erosion protection is probably a factor contributing to nest longevity, which may be as much as 100 years for Iridomyrmex. It is concluded that, despite the impressive size of the nests and the selective use of materials, neither species is very significant in terms of soil mixing when compared with the smaller, more common ant Aphaenogaster longiceps.